UNSPSC 51433905: Nilvadipine

This classification denotes a calcium channel blocker with the molecular formula C19H19N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0214FUT37J, chemically known as 3,5-pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester but generally known as nilvadipine, which bears US NIH Compound Identifier 4494. European Medicines Agency schedules Nilvadipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09292MIG.

UNSPSC 51433905 Nilvadipine is a Commodity-tier code for a specific antihypertensive medication used in emergency medical and health systems procurement. State and local governments soliciting under this code are primarily purchasing pharmaceutical products for emergency medical services and state health programs, with orders typically combining nilvadipine with other acute-care medications in multi-item contracts. The City of Tampa Fire Rescue's April 2026 IFB for Advanced Life Support Medications exemplifies the scope: sealed bids for emergency injectable medications including labetalol, epinephrine, adenosine, and diltiazem supplied to first-responder agencies, with firm pricing, nine-month minimum expiration dates, and ten-day delivery. The issuing bodies include city procurement offices managing emergency medical supply chains and state health agencies coordinating pharmacy benefit programs across multiple jurisdictions. Texas Health and Human Services Commission's April 2026 RFI for direct-to-manufacturer prescription programs and Minnesota's cooperative purchasing initiative for multi-source generics and OTC products signal expansion of state-level pharmaceutical procurement platforms that would encompass commodity medications like nilvadipine alongside broader inventory management.

Recent activity concentrates in Texas, Florida, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing a multi-state distribution model effective July 1, 2026, across participating state and local facilities. The City of Tampa's IFB (26P00188) closed April 8, 2026, with a $40,000 estimated contract value and SLBE sheltered-market designation including a 5 percent bid discount not to exceed $10,000; award was to be made within 120 days to the lowest responsive, responsible bidder with a one-year term and two optional one-year renewals. Minnesota's RFP (S1070000015802) for generic multi-source pharmaceuticals, due March 26, 2026, targets July 1, 2026, contract effectiveness through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with two-year terms and evaluation weighted heavily on price competitiveness (75 percent). Vendors must maintain cGMP and DSCSA compliance, supply insurance of $5 million general liability, and accept 3 percent administrative fees with performance penalties of $200 to $1,500 per violation.